Based on the assumption that defective CD8+ T-cell immunity to EBV leads to CNS colonization by EBV-infected autoreactive B cells (21, 22), adoptive immunotherapy with in vitro-expanded autologous T cells directed against EBV latent proteins was recently used to treat MS patients (78). This evidence concerns the gene CD8A and myeloid sarcoma.